ArticleFrontiers in pharmacology2026
PCSK9 inhibition alleviates sepsis-induced myocardial dysfunction by facilitating PINK1/parkin-associated mitophagy.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Sepsis-induced myocardial dysfunction (SIMD), also known as septic cardiomyopathy in sepsis patients is associated with worse prognosis and higher mortality compared to sepsis cases without SIMD. Early intervention and comprehensive management are crucial for improving survival, particularly in the early stages of sepsis. Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a promising therapeutic target in the cardiovascular system. While PCSK9 has been implicated in cardiovascular inflammation and injury, specific evidence regarding the potential of PCSK9 inhibition to mitigate SIMD remains limited. Methods: An Results: The SIMD models were successfully established both Conclusion: These findings suggest that the protective effects of PCSK9 inhibition against SIMD are closely associated with the enhancement of mitophagy and the modulation of the PINK1/Parkin pathway. Furthermore, this intervention correlates with attenuated oxidative stress, inflammation, and apoptosis, ultimately offering a potential therapeutic strategy for myocardial injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.